The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance
The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. J L Chiasson , R G Josse , L A Leiter , M Mihic , D M Nathan , C Palmason , R M Cohen and T M Wolever Research Center, Hôtel-Dieu de Montréal, Toronto, Canada. chiassoj@ere.montreal.ca Abstract OBJECTIVE: To s...
Saved in:
Published in | Diabetes care Vol. 19; no. 11; pp. 1190 - 1193 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Alexandria, VA
American Diabetes Association
01.11.1996
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance.
J L Chiasson ,
R G Josse ,
L A Leiter ,
M Mihic ,
D M Nathan ,
C Palmason ,
R M Cohen and
T M Wolever
Research Center, Hôtel-Dieu de Montréal, Toronto, Canada. chiassoj@ere.montreal.ca
Abstract
OBJECTIVE: To study the effect of acarbose, an alpha-glucosidase inhibitor, on postprandial plasma glucose and insulin and
insulin sensitivity in subjects with impaired glucose tolerance (IGT). RESEARCH DESIGN AND METHODS: Subjects with IGT were
randomly treated in a double-blind fashion with placebo (n = 10) or acarbose (n = 8) at 100 mg t.i.d. for 4 months. All subjects
were submitted before randomization and at the end of the study to a standardized breakfast and a 12-h daytime plasma glucose
and plasma insulin profile, and insulin sensitivity was measured as steady-state plasma glucose (SSPG) using the insulin suppression
test. RESULTS: While placebo had no effect on postprandial plasma glucose and plasma insulin incremental area under the curve
(AUC) (3.03 +/- 0.5 vs. 3.76 +/- 0.6 mmol.h-1.l-1, P = NS; 1,488 +/- 229 vs. 1,609 +/- 253 pmol.h-1.l-1, P = NS), acarbose
resulted in a significant reduction for both glucose (1.44 +/- 0.3 vs. 4.45 +/- 0.9 mmol.h-1.l-1, P = 0.002) and insulin (626.7
+/- 104.3 vs. 1,338.3 +/- 220.5 pmol.h-1.l-1, P = 0.003). The reduction in 12-h plasma glucose and insulin AUC on acarbose
(11.2 +/- 2.1 mmol.h-1.l-1 and 7.5 +/- 0.7 nmol.h-1.l-1) was significantly greater than that on placebo (4.0 +/- 1.6 mmol.h-1.l-1
and 0.8 +/- 0.4 nmol.h-1.l-1) (P = 0.014 and 0.041). While SSPG was not affected by placebo (13.9 +/- 0.4 vs. 13.8 +/- 0.3
mmol/l; P = NS), it was significantly improved by acarbose (10.9 +/- 1.4 vs. 13.1 +/- 1.5 mmol/l, P < 0.004) and was also
significantly different from placebo at 4 months (P < 0.02). CONCLUSIONS: It is concluded that in subjects with IGT, acarbose
treatment decreases postprandial plasma glucose and insulin and improves insulin sensitivity. Acarbose may therefore be potentially
useful to prevent the progression of IGT to NIDDM. |
---|---|
Bibliography: | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 ObjectType-News-3 content type line 23 |
ISSN: | 0149-5992 1935-5548 |
DOI: | 10.2337/diacare.19.11.1190 |